Neurocrine Biosciences Inc (NBIX)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | 0 | 335,100 | 317,900 |
| Total stockholders’ equity | US$ in thousands | 2,589,700 | 2,232,000 | 1,707,800 | 1,374,000 | 1,126,200 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.20 | 0.22 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $2,589,700K)
= 0.00
Neurocrine Biosciences Inc's debt-to-capital ratio has shown a declining trend over the years, indicating a decreasing reliance on debt financing in relation to its total capital structure. As of December 31, 2020, the ratio stood at 0.22, reflecting that around 22% of the company's capital was debt-funded. Subsequently, by December 31, 2021, the ratio improved to 0.20.
The significant drop to 0.00 as of December 31, 2022, and maintained at 0.00 in the consecutive years, signifies that the company has effectively eliminated its debt relative to its total capital, resulting in a debt-free capital structure by the end of 2022. This might indicate a strong financial position and reduced financial risk for Neurocrine Biosciences Inc as it relies more on equity financing rather than debt.
Peer comparison
Dec 31, 2024